CN113384594A - 一种祛痘药物配方及其药物制备装置 - Google Patents
一种祛痘药物配方及其药物制备装置 Download PDFInfo
- Publication number
- CN113384594A CN113384594A CN202110682102.6A CN202110682102A CN113384594A CN 113384594 A CN113384594 A CN 113384594A CN 202110682102 A CN202110682102 A CN 202110682102A CN 113384594 A CN113384594 A CN 113384594A
- Authority
- CN
- China
- Prior art keywords
- parts
- acne
- acyclovir
- metronidazole
- cefalexin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 46
- 208000002874 Acne Vulgaris Diseases 0.000 title claims abstract description 32
- 206010000496 acne Diseases 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title claims description 8
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims abstract description 48
- 239000002775 capsule Substances 0.000 claims abstract description 42
- 239000000499 gel Substances 0.000 claims abstract description 42
- BITDLWAQPKSXTF-UHFFFAOYSA-M 1-[(3-nitrophenyl)methoxymethyl]pyridin-1-ium;chloride Chemical compound [Cl-].[O-][N+](=O)C1=CC=CC(COC[N+]=2C=CC=CC=2)=C1 BITDLWAQPKSXTF-UHFFFAOYSA-M 0.000 claims abstract description 39
- 229940106164 cephalexin Drugs 0.000 claims abstract description 39
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 claims abstract description 39
- 229960002581 moroxydine hydrochloride Drugs 0.000 claims abstract description 39
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims abstract description 36
- 229960004150 aciclovir Drugs 0.000 claims abstract description 36
- 238000003756 stirring Methods 0.000 claims abstract description 35
- 229960000282 metronidazole Drugs 0.000 claims abstract description 34
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims abstract description 34
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims abstract description 23
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 claims abstract description 23
- 238000001467 acupuncture Methods 0.000 claims abstract description 23
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 23
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims abstract description 23
- 229960003957 dexamethasone Drugs 0.000 claims abstract description 23
- 229960004194 lidocaine Drugs 0.000 claims abstract description 23
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 claims abstract description 23
- 229960005287 lincomycin Drugs 0.000 claims abstract description 23
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 20
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 20
- 239000003906 humectant Substances 0.000 claims abstract description 20
- 239000002904 solvent Substances 0.000 claims abstract description 20
- 239000003755 preservative agent Substances 0.000 claims abstract description 16
- 230000002335 preservative effect Effects 0.000 claims abstract description 16
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229920002125 Sokalan® Polymers 0.000 claims abstract description 13
- 229960001631 carbomer Drugs 0.000 claims abstract description 13
- 229940079593 drug Drugs 0.000 claims abstract description 9
- 235000015110 jellies Nutrition 0.000 claims abstract description 6
- 239000008274 jelly Substances 0.000 claims abstract description 6
- 239000000203 mixture Substances 0.000 claims description 13
- 239000000843 powder Substances 0.000 claims description 9
- 239000004744 fabric Substances 0.000 claims description 8
- 239000011229 interlayer Substances 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 235000017166 Bambusa arundinacea Nutrition 0.000 claims description 6
- 235000017491 Bambusa tulda Nutrition 0.000 claims description 6
- 241001330002 Bambuseae Species 0.000 claims description 6
- 235000015334 Phyllostachys viridis Nutrition 0.000 claims description 6
- 239000011425 bamboo Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 229940049638 carbomer homopolymer type c Drugs 0.000 claims description 3
- 229940043234 carbomer-940 Drugs 0.000 claims description 3
- 230000007935 neutral effect Effects 0.000 claims description 3
- 229940083608 sodium hydroxide Drugs 0.000 claims description 3
- 239000013583 drug formulation Substances 0.000 claims 4
- 230000000694 effects Effects 0.000 abstract description 6
- 230000003750 conditioning effect Effects 0.000 abstract description 3
- 235000005911 diet Nutrition 0.000 abstract description 2
- 230000037213 diet Effects 0.000 abstract description 2
- 208000020154 Acnes Diseases 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 8
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical group [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 4
- 239000005711 Benzoic acid Substances 0.000 description 4
- 241001104824 Nitraria tangutorum Species 0.000 description 4
- 230000002421 anti-septic effect Effects 0.000 description 4
- 235000010233 benzoic acid Nutrition 0.000 description 4
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 229940068968 polysorbate 80 Drugs 0.000 description 4
- 229920000053 polysorbate 80 Polymers 0.000 description 4
- 239000004302 potassium sorbate Substances 0.000 description 4
- 235000010241 potassium sorbate Nutrition 0.000 description 4
- 229940069338 potassium sorbate Drugs 0.000 description 4
- 239000010410 layer Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- POCJOGNVFHPZNS-ZJUUUORDSA-N (6S,7R)-2-azaspiro[5.5]undecan-7-ol Chemical compound O[C@@H]1CCCC[C@]11CNCCC1 POCJOGNVFHPZNS-ZJUUUORDSA-N 0.000 description 1
- TVEXGJYMHHTVKP-UHFFFAOYSA-N 6-oxabicyclo[3.2.1]oct-3-en-7-one Chemical compound C1C2C(=O)OC1C=CC2 TVEXGJYMHHTVKP-UHFFFAOYSA-N 0.000 description 1
- BSPUVYFGURDFHE-UHFFFAOYSA-N Nitramine Natural products CC1C(O)CCC2CCCNC12 BSPUVYFGURDFHE-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- POCJOGNVFHPZNS-UHFFFAOYSA-N isonitramine Natural products OC1CCCCC11CNCCC1 POCJOGNVFHPZNS-UHFFFAOYSA-N 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 235000021142 long-term diet Nutrition 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B02—CRUSHING, PULVERISING, OR DISINTEGRATING; PREPARATORY TREATMENT OF GRAIN FOR MILLING
- B02C—CRUSHING, PULVERISING, OR DISINTEGRATING IN GENERAL; MILLING GRAIN
- B02C18/00—Disintegrating by knives or other cutting or tearing members which chop material into fragments
- B02C18/06—Disintegrating by knives or other cutting or tearing members which chop material into fragments with rotating knives
- B02C18/08—Disintegrating by knives or other cutting or tearing members which chop material into fragments with rotating knives within vertical containers
- B02C18/10—Disintegrating by knives or other cutting or tearing members which chop material into fragments with rotating knives within vertical containers with drive arranged above container
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B02—CRUSHING, PULVERISING, OR DISINTEGRATING; PREPARATORY TREATMENT OF GRAIN FOR MILLING
- B02C—CRUSHING, PULVERISING, OR DISINTEGRATING IN GENERAL; MILLING GRAIN
- B02C18/00—Disintegrating by knives or other cutting or tearing members which chop material into fragments
- B02C18/06—Disintegrating by knives or other cutting or tearing members which chop material into fragments with rotating knives
- B02C18/16—Details
- B02C18/18—Knives; Mountings thereof
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B02—CRUSHING, PULVERISING, OR DISINTEGRATING; PREPARATORY TREATMENT OF GRAIN FOR MILLING
- B02C—CRUSHING, PULVERISING, OR DISINTEGRATING IN GENERAL; MILLING GRAIN
- B02C18/00—Disintegrating by knives or other cutting or tearing members which chop material into fragments
- B02C18/06—Disintegrating by knives or other cutting or tearing members which chop material into fragments with rotating knives
- B02C18/16—Details
- B02C18/24—Drives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
一种祛痘药物配方，涉及制药技术领域；包括以下药物质量份数：林可霉素利多卡因凝胶2‑7份、皮康王10‑20份、地塞米松针刺剂1‑1.5份、盐酸吗啉胍2.7‑3.8份、头孢氨苄胶囊1.5‑3.2份、甲硝锉片0.8‑1.4份、阿昔洛韦0.03‑0.5份、卡波姆0.2‑0.8份、氢氧化钠、保湿剂、增溶剂、抗氧剂、防腐剂。现有技术中祛痘药物或饮食调理时间久的问题；通过制作林可霉素利多卡因凝胶、皮康王、地塞米松针刺剂混合搅拌得林可霉素利多卡因凝胶、皮康王、地塞米松针刺剂的混合胶状物与头孢氨苄胶囊、盐酸吗啉胍片、甲硝锉片、阿昔洛韦的混合凝胶混合得祛痘药物可高效祛痘，效果明显且时间短，利于推广。
Description
技术领域
本发明涉及制药技术领域，更具体的说，本发明涉及一种祛痘药物配方及其药物制备装置。
背景技术
痘痘是一种毛囊皮脂腺的慢性炎症性疾病，年轻人非常讨厌痘痘，痘痘不仅带给人疼或痒等不适感觉，还会影响样貌，而目前对于痘痘的消除药物很多，但其效果并不明显，一般是由自然生长去除或是饮食长期调理让其消失，时间久，因此，提出一种祛痘药物配方来解决问题。
发明内容
本发明旨在于解决现有技术中祛痘药物或饮食调理时间久的技术问题。
本发明的目的与功效，由以下具体技术手段所达成：
一种祛痘药物配方，包括以下药物质量份数：林可霉素利多卡因凝胶2-7份、皮康王10-20份、地塞米松针刺剂1-1.5份、盐酸吗啉胍2.7-3.8份、头孢氨苄胶囊1.5-3.2份、甲硝锉片0.8-1.4份、阿昔洛韦0.03-0.5份、卡波姆0.2-0.8份、氢氧化钠、保湿剂、增溶剂、抗氧剂、防腐剂。
优选的，林可霉素利多卡因凝胶4.5份、皮康王15份、地塞米松针刺剂1.25份、盐酸吗啉胍3.25份、头孢氨苄胶囊2.35份、甲硝锉片1.1份、阿昔洛韦0.265份、卡波姆0.5份、氢氧化钠、保湿剂、增溶剂、抗氧剂、防腐剂。
优选的，林可霉素利多卡因凝胶、皮康王、地塞米松针刺剂混合搅拌得林可霉素利多卡因凝胶、皮康王、地塞米松针刺剂的混合胶状物。
优选的，盐酸吗啉胍、头孢氨苄胶囊、甲硝锉片、阿昔洛韦粉碎混合制成盐酸吗啉胍、头孢氨苄胶囊、甲硝锉片、阿昔洛韦的混合凝胶。
优选的，盐酸吗啉胍、头孢氨苄胶囊、甲硝锉片、阿昔洛韦的混合凝胶制备方法如下：
S1：材料准备，准备盐酸吗啉胍片、头孢氨苄胶囊、甲硝锉片、阿昔洛韦、卡波姆、氢氧化钠、增溶剂、保湿剂、抗氧剂、防腐剂；
S2：材料加工：将盐酸吗啉胍片、甲硝锉片粉碎混合，将头孢氨苄胶囊的胶囊外衣去除，将头孢氨苄胶囊的粉剂与盐酸吗啉胍片、甲硝锉片、阿昔洛韦细粉混合得粉状混合物；
S3:制作凝胶：准备头孢氨苄胶囊、盐酸吗啉胍片、甲硝锉片、阿昔洛韦细粉的粉状混合物质量比1:1的水，将浓度为0.85%的卡波姆940与水放在制作杯中充分搅拌，将粉状混合物和氢氧化钠同时加入制作杯，调节PH值至中性，依次放入增溶剂、保湿剂、抗氧剂、防腐剂搅拌均匀得头孢氨苄胶囊、盐酸吗啉胍片、甲硝锉片、阿昔洛韦的混合凝胶。
优选的，头孢氨苄胶囊、盐酸吗啉胍片、甲硝锉片、阿昔洛韦的混合凝胶与林可霉素利多卡因凝胶、皮康王、地塞米松针刺剂的混合胶状物混合得祛痘药物。
本发明提供一种祛痘药物制备装置，包括外壳、壳盖、粉碎刀轴和收集桶，外壳顶部开口处开合设置有壳盖，壳盖顶部下端转动设置有粉碎刀轴，壳盖顶部上端安装有带动粉碎刀轴旋转的电机，外壳内部上端设有导向块，导向块中心设有粉碎腔，且粉碎腔呈漏斗状，粉碎刀轴下端位于粉碎腔内，粉碎腔下端固定有筛网组件，筛网组件包括环板架和筛网，环板架内侧设有环形的夹层槽，筛网活动设置于夹层槽内，导向块底部固定设置连接环，连接环中心设置有横向移动的联动杆，联动杆上端与筛网之间固定有固定杆，联动杆下端固定有齿条，外壳底部对应粉碎腔设有限位筒，限位筒一侧设有夹持件，限位筒内设有通过夹持件夹持的收集桶，收集桶内部转动设置有搅拌杆，搅拌杆上端与齿条啮合卡接。
优选的，环板架上下端均呈漏斗状，且相对设置。
优选的，收集桶内部两侧设有竖槽，收集桶内部下端设有若干环槽，搅拌杆包括搅拌轴、搅拌叶片，搅拌轴两侧设有搅拌叶片，搅拌叶片与环槽对应设置。
有益效果：
1、这种祛痘药物配方通过制作林可霉素利多卡因凝胶、皮康王、地塞米松针刺剂混合搅拌得林可霉素利多卡因凝胶、皮康王、地塞米松针刺剂的混合胶状物与头孢氨苄胶囊、盐酸吗啉胍片、甲硝锉片、阿昔洛韦的混合凝胶混合得祛痘药物可高效祛痘，效果明显且时间短，利于推广。
附图说明：
图1为本发明的祛痘药物实验数据对比示意图。
图2为本发明的药物制备装置主视剖面示意图。
图3为本发明的连接环、收集桶、筛网组件爆炸示意图。
图4为本发明的收集桶俯视示意图。
图5为本发明的图2中A处放大示意图。
图6为本发明的筛网组件主视剖面示意图。
图1-6中：外壳1、壳盖2、粉碎刀轴3、导向块4、滑槽41、连接环5、联动杆51、滑块52、固定杆53、筛网组件6、环板架61、筛网62、夹层槽63、限位筒7、收集桶8、竖槽81、搅拌杆82、搅拌轴821、搅拌叶片822、环槽83、夹持件9、夹板91、连接杆92、齿条10、电动推杆11。
具体实施方式
下面将结合本发明实施例中的附图，对本发明实施例中的技术方案进行清楚、完整地描述，显然，所描述的实施例仅仅是本发明一部分实施例，而不是全部的实施例。
参照图1，一种祛痘药物配方，包括以下药物质量份数：林可霉素利多卡因凝胶2-7份、皮康王10-20份、地塞米松针刺剂1-1.5份、盐酸吗啉胍2.7-3.8份、头孢氨苄胶囊1.5-3.2份、甲硝锉片0.8-1.4份、阿昔洛韦0.03-0.5份、卡波姆0.2-0.8份、氢氧化钠、保湿剂、增溶剂、抗氧剂、防腐剂。
其中，林可霉素利多卡因凝胶4.5份、皮康王15份、地塞米松针刺剂1.25份、盐酸吗啉胍3.25份、头孢氨苄胶囊2.35份、甲硝锉片1.1份、阿昔洛韦0.265份、卡波姆0.5份、氢氧化钠、保湿剂、增溶剂、抗氧剂、防腐剂；保湿剂可选乙醇，乙醇的用量选择药物总量的8%，增溶剂选择聚山梨酯-80，抗氧剂选用山梨酸钾、防腐剂用苯甲酸。
其中，林可霉素利多卡因凝胶、皮康王、地塞米松针刺剂混合搅拌得林可霉素利多卡因凝胶、皮康王、地塞米松针刺剂的混合胶状物。
其中，盐酸吗啉胍、头孢氨苄胶囊、甲硝锉片、阿昔洛韦粉碎混合制成盐酸吗啉胍、头孢氨苄胶囊、甲硝锉片、阿昔洛韦的混合凝胶。
其中，盐酸吗啉胍、头孢氨苄胶囊、甲硝锉片、阿昔洛韦的混合凝胶制备方法如下：
S1：材料准备，准备盐酸吗啉胍片、头孢氨苄胶囊、甲硝锉片、阿昔洛韦、卡波姆、氢氧化钠、增溶剂、保湿剂、抗氧剂、防腐剂；
S2：材料加工：将盐酸吗啉胍片、甲硝锉片粉碎混合，将头孢氨苄胶囊的胶囊外衣去除，将头孢氨苄胶囊的粉剂与盐酸吗啉胍片、甲硝锉片、阿昔洛韦细粉混合得粉状混合物；
S3:制作凝胶：准备头孢氨苄胶囊、盐酸吗啉胍片、甲硝锉片、阿昔洛韦细粉的粉状混合物质量比1:1的水，将浓度为0.85%的卡波姆940与水放在制作杯中充分搅拌，将粉状混合物和氢氧化钠同时加入制作杯，调节PH值至中性，依次放入增溶剂、保湿剂、抗氧剂、防腐剂搅拌均匀得头孢氨苄胶囊、盐酸吗啉胍片、甲硝锉片、阿昔洛韦的混合凝胶。
其中，头孢氨苄胶囊、盐酸吗啉胍片、甲硝锉片、阿昔洛韦的混合凝胶与林可霉素利多卡因凝胶、皮康王、地塞米松针刺剂的混合胶状物混合得祛痘药物。
实施案例1
林可霉素利多卡因凝胶4.5份、皮康王15份、地塞米松针刺剂1.25份、盐酸吗啉胍3.25份、头孢氨苄胶囊2.35份、甲硝锉片1.1份、阿昔洛韦0.265份、卡波姆0.5份、氢氧化钠、保湿剂、增溶剂、抗氧剂、防腐剂；保湿剂可选乙醇，乙醇的用量选择药物总量的8%，增溶剂选择聚山梨酯-80，抗氧剂选用山梨酸钾、防腐剂用苯甲酸。
实施案例2
林可霉素利多卡因凝胶2份、皮康王10份、地塞米松针刺剂1份、盐酸吗啉胍2.7份、头孢氨苄胶囊1.5份、甲硝锉片0.8份、阿昔洛韦0.03份、卡波姆0.2份、氢氧化钠、保湿剂、增溶剂、抗氧剂、防腐剂；保湿剂可选乙醇，乙醇的用量选择药物总量的8%，增溶剂选择聚山梨酯-80，抗氧剂选用山梨酸钾、防腐剂用苯甲酸。
实施案例3
林可霉素利多卡因凝胶7份、皮康王20份、地塞米松针刺剂1.5份、盐酸吗啉胍3.8份、头孢氨苄胶囊3.2份、甲硝锉片1.4份、阿昔洛韦0.5份、卡波姆0.8份、氢氧化钠、保湿剂、增溶剂、抗氧剂、防腐剂；保湿剂可选乙醇，乙醇的用量选择药物总量的8%，增溶剂选择聚山梨酯-80，抗氧剂选用山梨酸钾、防腐剂用苯甲酸。
参照图2-6，本实施例提供一种祛痘药物制备装置，包括外壳1、壳盖2、粉碎刀轴3和收集桶8，外壳1顶部开口处盖合有壳盖2，壳盖2与外壳1外侧安装有对应的锁扣，壳盖2顶部下端转动连接有粉碎刀轴3，壳盖2顶部上端固定安装有带动粉碎刀轴3旋转的电机，外壳1内部上端固定连接有导向块4，导向块4中心设有粉碎腔，且粉碎腔呈漏斗状，粉碎刀轴3下端位于粉碎腔内，粉碎腔下端固定有筛网组件6，筛网组件6包括环板架61和筛网62，环板架61固定在粉碎腔的下端，环板架61内侧设有环形的夹层槽63，筛网62滑动连接在夹层槽63内，且筛网62左右两端均与夹层槽63内部固定有弹簧，导向块4底部固定连接有连接环5，连接环5中心设置有横向贯穿的联动杆51，联动杆51上端位于连接环5的外侧均固定有T状的滑块52，导向块4底部左右两侧对应滑块52设有滑槽41，滑块52滑动设置与滑槽41内，且滑块52与滑槽41内一侧固定有弹簧，右侧的滑槽41内固定安装有电动推杆11，电动推杆11一端与滑块52固定连接，电动推杆11启动推动滑块52移动，滑块52带动联动杆51左右移动，联动杆51上端与筛网62之间固定有固定杆53，联动杆51下端固定有齿条10，外壳1底部对应粉碎腔固定连接有限位筒7，限位筒7一侧活动设置有夹持件9，夹持件9具体结构为：包括夹板91和连接杆92，夹板91为弧形板，弧形板位于限位筒7内部，弧形板远离限位筒7中心一侧固定有连接杆92，连接杆92远离弧形板一端延伸至限位筒7外侧固定有拉手，连接杆92位于限位筒7内套接有复位弹簧，限位筒7内设有通过夹持板91夹持的收集桶8，收集桶8内部转动连接有搅拌杆82，搅拌杆82上端与齿条10啮合卡接；将药片放入粉碎腔，启动电机带动粉碎刀轴3转动对药品进行粉碎，粉碎的药品通过筛网62落下落入收集桶8，在粉碎的过程中启动电动推杆11，电动推杆11带动联动杆51移动，进而带动筛网62在夹层槽63中左右移动，晃动的过程中使得药品粉碎更彻底，其次可防止筛网62堵塞，联动杆51左右移动过程中带动搅拌杆82转动，提前在收集桶8内放入水，进而可将药物可快速搅拌均匀。
其中，外壳1外侧对应收集桶8处设有门板；便于将收集桶8取出。
其中，环板架61上下端均呈漏斗状，且相对设置；粉碎的药粉易下落不会积存在环板架61上端。
其中，收集桶8内部两侧设有竖槽81，收集桶8内部下端设有若干环槽83，环槽83与竖槽81连通，搅拌杆82包括搅拌轴821、搅拌叶片822，搅拌轴821两侧固定有搅拌叶片822，搅拌叶片822与环槽83对应设置；搅拌轴821上端固定有齿轮与齿条10啮合，联动杆51带动齿条10左右移动的过程中，齿条10带动搅拌轴821转动，搅拌轴821带动搅拌叶片822在收集桶8内搅拌，通过搅拌轴821对应竖槽81可取出搅拌杆821，便于拆卸清洗。
工作原理：将药片放入粉碎腔，启动电机带动粉碎刀轴3转动对药品进行粉碎，粉碎的药品通过筛网62落下落入收集桶8，在粉碎的过程中启动电动推杆11，电动推杆11带动联动杆51移动，进而带动筛网62在夹层槽63中左右移动，晃动的过程中使得药品粉碎更彻底，其次可防止筛网62堵塞，联动杆51左右移动过程中带动搅拌杆82转动，提前在收集桶8内放入水，进而可将药物可快速搅拌均匀。
Claims (9)
1.一种祛痘药物配方，其特征在于，包括以下药物质量份数：林可霉素利多卡因凝胶2-7份、皮康王10-20份、地塞米松针刺剂1-1.5份、盐酸吗啉胍2.7-3.8份、头孢氨苄胶囊1.5-3.2份、甲硝锉片0.8-1.4份、阿昔洛韦0.03-0.5份、卡波姆0.2-0.8份、氢氧化钠、保湿剂、增溶剂、抗氧剂、防腐剂。
2.如权利要求1所述的祛痘药物配方，其特征在于，林可霉素利多卡因凝胶4.5份、皮康王15份、地塞米松针刺剂1.25份、盐酸吗啉胍3.25份、头孢氨苄胶囊2.35份、甲硝锉片1.1份、阿昔洛韦0.265份、卡波姆0.5份、氢氧化钠、保湿剂、增溶剂、抗氧剂、防腐剂。
3.如权利要求1所述的祛痘药物配方，其特征在于，所述林可霉素利多卡因凝胶、皮康王、地塞米松针刺剂混合搅拌得林可霉素利多卡因凝胶、皮康王、地塞米松针刺剂的混合胶状物。
4.如权利要求1所述的祛痘药物配方，其特征在于，所述盐酸吗啉胍、头孢氨苄胶囊、甲硝锉片、阿昔洛韦粉碎混合制成盐酸吗啉胍、头孢氨苄胶囊、甲硝锉片、阿昔洛韦的混合凝胶。
5.如权利要求4所述的祛痘药物配方，其特征在于，所述盐酸吗啉胍、头孢氨苄胶囊、甲硝锉片、阿昔洛韦的混合凝胶制备方法如下：
S1：材料准备，准备盐酸吗啉胍片、头孢氨苄胶囊、甲硝锉片、阿昔洛韦、卡波姆、氢氧化钠、增溶剂、保湿剂、抗氧剂、防腐剂；
S2：材料加工：将盐酸吗啉胍片、甲硝锉片粉碎混合，将头孢氨苄胶囊的胶囊外衣去除，将头孢氨苄胶囊的粉剂与盐酸吗啉胍片、甲硝锉片、阿昔洛韦细粉混合得粉状混合物；
S3:制作凝胶：准备头孢氨苄胶囊、盐酸吗啉胍片、甲硝锉片、阿昔洛韦细粉的粉状混合物质量比1:1的水，将浓度为0.85%的卡波姆940与水放在制作杯中充分搅拌，将粉状混合物和氢氧化钠同时加入制作杯，调节PH值至中性，依次放入增溶剂、保湿剂、抗氧剂、防腐剂搅拌均匀得头孢氨苄胶囊、盐酸吗啉胍片、甲硝锉片、阿昔洛韦的混合凝胶。
6.如权利要求5所述的祛痘药物配方，其特征在于，所述头孢氨苄胶囊、盐酸吗啉胍片、甲硝锉片、阿昔洛韦的混合凝胶与林可霉素利多卡因凝胶、皮康王、地塞米松针刺剂的混合胶状物混合得祛痘药物。
7.一种祛痘药物制备装置，包括外壳（1）、壳盖（2）、粉碎刀轴（3）和收集桶（8），其特征在于，所述外壳（1）顶部开口处开合设置有壳盖（2），壳盖（2）顶部下端转动设置有粉碎刀轴（3），壳盖（2）顶部上端安装有带动粉碎刀轴（3）旋转的电机，所述外壳（1）内部上端设有导向块（4），导向块（4）中心设有粉碎腔，且粉碎腔呈漏斗状，粉碎刀轴（3）下端位于粉碎腔内，所述粉碎腔下端固定有筛网组件（6），所述筛网组件（6）包括环板架（61）和筛网（62），所述环板架（61）内侧设有环形的夹层槽（63），所述筛网（62）活动设置于夹层槽（63）内，所述导向块（4）底部固定设置连接环（5），连接环（5）中心设置有横向移动的联动杆（51），联动杆（51）上端与筛网（62）之间固定有固定杆（53），所述联动杆（51）下端固定有齿条（10），所述外壳（1）底部对应粉碎腔设有限位筒（7），所述限位筒（7）一侧设有夹持件（9），所述限位筒（7）内设有通过夹持件（9）夹持的收集桶（8），所述收集桶（8）内部转动设置有搅拌杆（82），所述搅拌杆（82）上端与齿条（10）啮合卡接。
8.如权利要求7所述的祛痘药物制备装置，其特征在于，所述环板架（61）上下端均呈漏斗状，且相对设置。
9.如权利要求7所述的祛痘药物制备装置，其特征在于，所述收集桶（8）内部两侧设有竖槽（81），所述收集桶（8）内部下端设有若干环槽（83），所述搅拌杆（82）包括搅拌轴（821）、搅拌叶片（822），所述搅拌轴（821）两侧设有搅拌叶片（822），所述搅拌叶片（822）与环槽（83）对应设置。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110682102.6A CN113384594A (zh) | 2021-06-19 | 2021-06-19 | 一种祛痘药物配方及其药物制备装置 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110682102.6A CN113384594A (zh) | 2021-06-19 | 2021-06-19 | 一种祛痘药物配方及其药物制备装置 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113384594A true CN113384594A (zh) | 2021-09-14 |
Family
ID=77623065
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110682102.6A Pending CN113384594A (zh) | 2021-06-19 | 2021-06-19 | 一种祛痘药物配方及其药物制备装置 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113384594A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115054614A (zh) * | 2022-06-07 | 2022-09-16 | 付聪颖 | 一种根治面部痤疮的净颜膏及其制备方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1634115A (zh) * | 2004-11-17 | 2005-07-06 | 姜凤龙 | 清痘洁净霜 |
| CN204564004U (zh) * | 2015-05-04 | 2015-08-19 | 蒋光美 | 一种药学固体试剂粉碎及溶解一体机装置 |
-
2021
- 2021-06-19 CN CN202110682102.6A patent/CN113384594A/zh active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1634115A (zh) * | 2004-11-17 | 2005-07-06 | 姜凤龙 | 清痘洁净霜 |
| CN204564004U (zh) * | 2015-05-04 | 2015-08-19 | 蒋光美 | 一种药学固体试剂粉碎及溶解一体机装置 |
Non-Patent Citations (2)
| Title |
|---|
| 杨敏: "双黄消痤丸对兔耳痤疮模型毛囊面积、皮脂腺的影响", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》 * |
| 陈思宏等: "中西药联合治疗寻常型痤疮50例", 《北京中医》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115054614A (zh) * | 2022-06-07 | 2022-09-16 | 付聪颖 | 一种根治面部痤疮的净颜膏及其制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113102053B (zh) | 一种药剂科用颗粒药物粉碎混合设备 | |
| CN113384594A (zh) | 一种祛痘药物配方及其药物制备装置 | |
| CN216296148U (zh) | 一种中草药复合肉牛饲料用混合装置 | |
| CN111772201B (zh) | 一种柏籽收集用辅助去壳设备 | |
| CN115072853A (zh) | 一种含海蓬子素提取液的矿物质水的制备装置及制备方法 | |
| CN205462632U (zh) | 一种罗汉果破碎设备 | |
| CN211921366U (zh) | 一种水利工程用水草粉碎制肥设备 | |
| CN114208923A (zh) | 一种山茶油凝胶糖果的生产设备及其生产方法 | |
| CN217699503U (zh) | 一种西药学医疗用西药研磨装置 | |
| CN220460889U (zh) | 一种中药饮片粉碎装置 | |
| CN220716102U (zh) | 药物原料粉碎机 | |
| CN218774631U (zh) | 一种药粉搅拌装置 | |
| CN219114250U (zh) | 棱形制粒刀装置 | |
| CN216172920U (zh) | 一种东北雌性红萝卜粉制造用的粉碎设备 | |
| CN219702037U (zh) | 一种适用于三甲复脉制剂的中药研磨粉碎装置 | |
| CN218573600U (zh) | 一种可同时加工和造粒适用于复合肥生产的造粒装置 | |
| CN219396177U (zh) | 红枣粉加工装置 | |
| CN220990979U (zh) | 一种用于片剂制备的粉碎装置 | |
| CN211098717U (zh) | 一种用于药剂学制药用的快速配药装置 | |
| CN213825154U (zh) | 一种用于药材粉碎的粉碎装置 | |
| CN213000171U (zh) | 一种口服液生产用的提取装置 | |
| CN220715666U (zh) | 一种马度米星铵预混剂制备用原料提取设备 | |
| CN220310500U (zh) | 一种粉碎兽药装置 | |
| CN220328510U (zh) | 一种氧化锌制备用沉淀机构 | |
| CN216458302U (zh) | 一种活性氧消毒剂制造设备 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210914 |